From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model.

ABSTRACT: For the treatment of Type 2 Diabetes, high efficacy approaches such as Glucagon-like peptide 1 (GLP-1)-based therapies are recommended for glucose control. Prediction of the clinical outcome of these therapies on glucose and hemoglobin A1c (HbA1c), using early available pharmacokinetic and in vitro efficacy information, can be a valuable tool for compound selection and supporting drug development. Our previously developed glucose homeostasis model (the 4GI model) is a systems model that is able to quantify drug effects on glucose based on in vitro potency and PK information. In this research, the model was coupled to an existing integrated glucose-red blood cell-HbA1c (IGRH) model for predicting the effects of GLP-1 and GLP-1/glucagon (dual) receptor agonists, liraglutide and cotadutide, o

SUBMITTER: Bosch R 

PROVIDER: S-EPMC12439278 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature